Publication
Article
Improving Outcomes in Patients at Risk for Venous Thromboembolism Following Total Knee and Total Hip Replacement: Implications for Managed Care
The information presented in this supplement to The American Journal of Managed Care is based upon the conclusions and insights derived from a roundtable discussion, which identified means of overcoming barriers to improved outcomes for patients who have undergone surgery for total knee replacement (TKR) or total hip replacement (THR), and who are, consequently, at risk for venous thromboembolism (VTE). The diversity of the assembled healthcare professionals allowed for a wide-ranging discussion of clinical, institutional, and systemic approaches.
The roundtable and this publication were funded by Janssen Pharmaceuticals, Inc.; which included honoraria paid to the faculty members.
Faculty
Robert P. Navarro, PharmD (Moderator)
Clinical Professor
University of Florida—College of Pharmacy
Gainesville, Florida
James E. Barr, MD
Medical Director
Central Jersey Physician Network
Flemington, New Jersey
Karen Faubus, RN, BSN
Director
Clinical Pharmacy Services
Spur, Texas
Aman D. Sabharwal, MD, CPHM
Quality & Safety, and Revenue Cycle Management
Jackson Health System
Assistant Professor of Clinical Medicine
Florida International University College of Medicine
Fort Lauderdale, Florida
Electa Stern, PharmD
Clinical Supervisor, Pharmacy
Sharp Grossmont Hospital
La Mesa, California
Kevin Unger, MBA/MSHA, CHE
President and CEO
Poudre Valley Hospital
Fort Collins, Colorado
Faculty Disclosures
These faculty members have disclosed the following relevant commercial financial relationships or affiliations in the past 12 months:
James E. Barr, MD
Consultant: Johnson & Johnson
Karen Faubus, RN, BSN
Advisory board/consultant/honoraria: Janssen Pharmaceuticals, Inc
Aman D. Sabharwal, MD, CPHM
Advisory board/consultant: Janssen Pharmaceuticals, Inc
Electa Stern, PharmD
Advisory board/consultant: Boehringer Ingelheim
Kevin Unger, MBA/MSHA, CHE
Advisory board/honoraria: Janssen Pharmaceuticals, Inc
The following participant has nothing to disclose relevant to the content of this supplement:
Robert P. Navarro, PharmD
This supplement was supported by Janssen Pharmaceuticals, Inc.
The contents of this supplement may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.
Signed disclosures are on file at the office of The American Journal of Managed Care, Plainsboro, New Jersey.
Publisher’s Note
The opinions expressed in this supplement are those of the authors, presenters, and/or panelists and are not attributable to the sponsor or the publisher, editor, or editorial board of The American Journal of Managed Care. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this supplement are not necessarily the same as indicated in the package insert for the product and may reflect the clinical experience of the authors, presenters, and/or panelists or may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.
Supplement Policy Statement
Standards for Supplements to The American Journal of Managed Care
All supplements to The American Journal of Managed Care are designed to facilitate and enhance ongoing medical education in various therapeutic disciplines. All Journal supplements adhere to standards of fairness and objectivity, as outlined below. Supplements to The American Journal of Managed Care will: